ArticleOncogene2026
PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Protein post-translational modifications are crucial in driving cancer development and progression. The SUMO E3 ligase PIAS4 regulates various cellular processes, thereby promoting tumour advancement. However, the role of PIAS4 in breast cancer remains unclear. This study aimed to examine the protein levels of PIAS4 in clinical specimens, explore PIAS4 regulates cell cycle mechanism and investigate the synergistic inhibitory effects of PIAS4 and CDK6 inhibition on breast cancer progression. Our findings revealed that PIAS4 was highly expressed in breast cancer and negatively correlated with prognosis. Abrogation of PIAS4 inhibited breast cancer cell proliferation and induced G1 phase cell cycle delay. The primary mechanism involved PIAS4-mediated SUMOylation of CDK6, which enhanced retinoblastoma 1 (RB1) phosphorylation and the transcription of downstream cell cycle genes, facilitating cell cycle G1 phase progression. We found that CDK6 underwent SUMO1 and SUMO2/3 modifications and identified the main SUMO2/3 modification sites. Mutations at these sites inhibit CDK6-mediated RB1 phosphorylation, consequently blocking cell cycle progression in the G1 phase. CDK6 kinase activity is reduced following PIAS4 knockdown, which may be associated with decreased binding of Cyclin D1 to CDK6. Moreover, in mouse xenograft models, combining PIAS4 and CDK6 inhibition enhanced therapeutic efficacy against breast cancer. Therefore, targeting PIAS4 to impede cell cycle progression may be a novel strategy for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.